IFN Beta 1B

100% Secure

Recombinant Human Interferon Beta 1B

Product Type
Recombinant Protein
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
OBT1547 FN 10 µg
Recombinant human interferon beta 1b produced in E. coli is a single non-glycosylated variant form of the human interferon beta-1b polypeptide chain. The interferon gene was cloned from human fibroblasts and altered to substitute Serine for the Cysteine at residue 17.

Product Details

Target Species
Human
Product Form
Purified Recombinant protein - lyophilised.
Reconstitution
Reconstitute with 0.1ml distilled water.
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
Preparation
Purified recombinant Interferon beta 1b expressed in E. coli.
Buffer Solution
Lyophilised from a solution containing human albumin and dextrose.
Preservative Stabilisers
None present
Activity
The Specific activity determined using a viral resistance assay is of 32 x 106 IU/mg.
The viral resistance assays used are the human WISH cell line and VSV, or the monkey VERO cell line and EMCV.
Purity
>98% by SDS PAGE and HPLC analysis.
Approx. Protein Concentrations
0.1 mg/ml after reconstitution
Molecular Weight
18.5 kDa (165 amino acid residues)

Storage Information

Storage
Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
3 months from date of reconstitution.

More Information

UniProt
P01574 Related reagents
Entrez Gene
IFNB1 Related reagents
GO Terms
GO:0003714 transcription corepressor activity
GO:0007596 blood coagulation
GO:0005125 cytokine activity
GO:0005132 interferon-alpha/beta receptor binding
GO:0005615 extracellular space
GO:0006917 induction of apoptosis
GO:0006919 activation of caspase activity
GO:0008285 negative regulation of cell proliferation
GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter
GO:0030101 natural killer cell activation
GO:0032897 negative regulation of viral transcription
GO:0042100 B cell proliferation
GO:0045071 negative regulation of viral genome replication
GO:0045089 positive regulation of innate immune response
GO:0045343 regulation of MHC class I biosynthetic process
GO:0046597 negative regulation of virion penetration into host cell
GO:0051607 defense response to virus
GO:0060337 type I interferon-mediated signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0071360 cellular response to exogenous dsRNA
Regulatory
For research purposes only

Applications of IFN Beta 1B

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Functional Assays
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Specific References

References for IFN Beta 1B

  1. Happold, C. et al. (2014) Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells.
    Mol Cancer Ther. 13: 948-61.
  2. Wolpert, F. et al. (2015) Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.
    PLoS One. 10 (10): e0139603.
  3. Eriksen, A.B. et al. (2015) Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 278: 11-8.